Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasias
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Objective: To assess the utility of serum neurofilament for diagnosis and monitoring of primary progressive aphasia (PPA) variants. Methods: We investigated neurofilament light chain (NF-L) levels in blood of 99 patients with PPA (40 with nonfluent variant PPA [nfvPPA], 38 with semantic variant PPA [svPPA], 21 with logopenic variant PPA [lvPPA]) and compared diagnostic performance with that reached by CSF NF-L, phosphorylated neurofilament heavy chain (pNF-H), β-amyloid (Aβ1-42), tau, and phosphorylated tau. The longitudinal change of blood NF-L levels was measured and analyzed for correlation with functional decline and brain atrophy. Results: Serum NF-L is increased in PPA compared to controls and discriminates between nfvPPA/svPPA and lvPPA with 81% sensitivity and 67% specificity (cutoff 31 pg/mL). CSF NF-L, pNF-H, tau, phosphorylated tau, and Aβ1-42 achieved similar performance, and pNF-H was the only marker for discrimination of nfvPPA from svPPA/lvPPA. In most patients with nfvPPA and svPPA, but not lvPPA, serum NF-L increased within follow-up. The increase correlated with functional decline and progression of atrophy of the left frontal lobe of all patients with PPAs and the right middle frontal gyrus of patients with nfvPPA and svPPA. Conclusions: Blood level of NF-L can aid the differential diagnosis of PPA variants, especially in combination with CSF pNF-H. Because serum NF-L correlates with functional decline and atrophy in the disease course, it qualifies as an objective disease status marker. Extended follow-up studies with cases of known neuropathology are imperative. Classification of evidence: This study provides Class I evidence that in patients with PPA, blood levels of NF-L can distinguish the logopenic variant from the nonfluent/agrammatic and semantic variants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Classification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141
Kuhle, J., Barro, C., Andreasson, U., Derfuss, T., Lindberg, R., Sandelius, Å., Liman, V., Norgren, N., Blennow, K., & Zetterberg, H. (2016) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-1195 · Cited by 740
Development of methodology for conducting clinical trials in frontotemporal lobar degeneration
Knopman, D. S., Kramer, J. H., Boeve, B. F., Caselli, R. J., Graff-Radford, N. R., Mendez, M. F., Miller, B. L., & Mercaldo, N. (2008) · Brain · doi:10.1093/brain/awn234 · Cited by 442
Bacioglu, M., Maia, L. F., Preische, O., Schelle, J., Apel, A., Kaeser, S. A., Schweighauser, M., Eninger, T., Lambert, M., Pilotto, A., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.05.018 · Cited by 435
CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival
Skillbäck, T., Farahmand, B., Bartlett, J. W., Rosén, C., Mattsson, N., Nägga, K., Kilander, L., Religa, D., Wimo, A., Winblad, B., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000001015 · Cited by 263
Scherling, C. S., Hall, T., Berisha, F., Klepac, K., Karydas, A., Coppola, G., Kramer, J. H., Rabinovici, G., Ahlijanian, M., Miller, B. L., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24052 · Cited by 249 · cited 1×
“Studies examining FTLD– TARDNA-binding protein and FTLD-tau CSF samples provide evidence that TAR DNA-binding protein-43 pathology is associated with higher NF-L levels.(3,4,24) We found similar NF-L levels in the CSF and a trend for higher serum NF-L levels in the serum of nfvPPA compared to svPPA.”
Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia
Landqvist Waldö, M., Frizell Santillo, A., Passant, U., Zetterberg, H., Rosengren, L., Nilsson, C., & Englund, E. (2013) · BMC Neurology · doi:10.1186/1471-2377-13-54 · Cited by 127 · cited 1×
“Studies examining FTLD– TARDNA-binding protein and FTLD-tau CSF samples provide evidence that TAR DNA-binding protein-43 pathology is associated with higher NF-L levels.(3,4,24) We found similar NF-L levels in the CSF and a trend for higher serum NF-L levels in the serum of nfvPPA compared to svPPA.”
Pijnenburg, Y. A. L., Verwey, N. A., van der Flier, W. M., Scheltens, P., & Teunissen, C. E. (2015) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.11.001 · Cited by 91 · cited 1×
“Studies examining FTLD– TARDNA-binding protein and FTLD-tau CSF samples provide evidence that TAR DNA-binding protein-43 pathology is associated with higher NF-L levels.(3,4,24) We found similar NF-L levels in the CSF and a trend for higher serum NF-L levels in the serum of nfvPPA compared to svPPA.”
Frings, L., Mader, I., Landwehrmeyer, B. G., Weiller, C., Hüll, M., & Huppertz, H. (2012) · Human Brain Mapping · doi:10.1002/hbm.21304 · Cited by 38
Self-citation
Research works printed but not linked: 29
- 10.1080/02687038.2014.929631 · DOI
- 10.1212/WNL.0000000000003154 · DOI · Paper page
- 10.1007/s00115-011-3261-3 · DOI
- 10.1016/j.cortex.2016.07.004 · DOI
- 10.1016/0022-3956(75)90026-6 · DOI · Paper page
- 10.1212/WNL.43.11.2412-a · DOI · Paper page
- 10.1016/j.neuroimage.2009.10.066 · DOI
- 10.1002/mds.26715 · DOI · Paper page
- 10.1016/j.neuroimage.2007.09.031 · DOI · Paper page
- 10.1176/appi.ajp.162.7.1256 · DOI · Paper page
- 10.3174/ajnr.A2514 · DOI
- 10.1016/j.mri.2015.12.031 · DOI
- 10.1111/ene.12902 · DOI · Paper page
- 10.1371/journal.pone.0075091 · DOI · Paper page
- 10.1212/WNL.0000000000000261 · DOI · Paper page
- 10.1212/WNL.0b013e3182574f79 · DOI · Paper page
- 10.1111/jnc.13669 · DOI · Paper page
- 10.3233/JAD-141122 · DOI · Paper page
- 10.1007/s00415-011-5960-x · DOI
- 10.1089/neu.2015.4295 · DOI · Paper page
- 10.1002/ana.24552 · DOI · Paper page
- 10.1186/alzrt163 · DOI · Paper page
- 10.1162/jocn.1996.8.2.135 · DOI · Paper page
- 10.1093/brain/awl078 · DOI · Paper page
- 10.1212/WNL.0000000000001642 · DOI · Paper page
- Steinacker P, Feneberg E, Weishaupt J, et al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry 2016;87:12–20.
- 10.1038/nrneurol.2009.216 · DOI · Paper page
- 10.1007/s00401-011-0839-6 · DOI · Paper page
- 10.1212/WNL.0b013e3181ed9c52 · DOI · Paper page
Cited by
Neurofilaments as biomarkers in neurological disorders
Khalil, M., Teunissen, C. E., Otto, M., Piehl, F., Sormani, M. P., Gattringer, T., Barro, C., Kappos, L., Comabella, M., Fazekas, F., et al. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0058-z · Cited by 1,988
Self-citationNeurofilament light chain as a biomarker in neurological disorders
Gaetani, L., Blennow, K., Calabresi, P., Di Filippo, M., Parnetti, L., & Zetterberg, H. (2019) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-320106 · Cited by 1,334
Post-Stroke Cognitive Impairment and Dementia
Rost, N. S., Brodtmann, A., Pase, M. P., van Veluw, S. J., Biffi, A., Duering, M., Hinman, J. D., & Dichgans, M. (2022) · Circulation Research · doi:10.1161/circresaha.122.319951 · Cited by 790
Byrne, L. M., Rodrigues, F. B., Blennow, K., Durr, A., Leavitt, B. R., Roos, R. A. C., Scahill, R. I., Tabrizi, S. J., Zetterberg, H., Langbehn, D., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30124-2 · Cited by 364
Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease
Lewczuk, P., Ermann, N., Andreasson, U., Schultheis, C., Podhorna, J., Spitzer, P., Maler, J. M., Kornhuber, J., Blennow, K., & Zetterberg, H. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0404-9 · Cited by 305
Self-citation
Metadata
- Authors
- Steinacker, P., Semler, E., Anderl-Straub, S., Diehl-Schmid, J., Schroeter, M. L., Uttner, I., Foerstl, H., Landwehrmeyer, B., von Arnim, C. A. F., Kassubek, J., Oeckl, P., Huppertz, H.-J., Fassbender, K., Fliessbach, K., Prudlo, J., Roßmeier, C., Kornhuber, J., Schneider, A., Volk, A. E., Lauer, M., Danek, A., Ludolph, A. C., & Otto, M.
- Venue
- Neurology
- Published
- 2017-03-07
- Volume
- 88
- Issue
- 10
- Pages
- 961-969
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2587397868
- Cited by
- 89
- References
- 9
- FWCI
- 9.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasias. https://app.cochat.ai/papers/10.1212/wnl.0000000000003688
- The paper
- Steinacker, P., Semler, E., Anderl-Straub, S., Diehl-Schmid, J., Schroeter, M. L., Uttner, I., Foerstl, H., Landwehrmeyer, B., von Arnim, C. A. F., Kassubek, J., Oeckl, P., Huppertz, H.-J., Fassbender, K., Fliessbach, K., Prudlo, J., Roßmeier, C., Kornhuber, J., Schneider, A., Volk, A. E., . . . Otto, M. (2017). Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasias. Neurology. https://doi.org/10.1212/wnl.0000000000003688
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.